Background: Sertoli-Leydig cell tumours of the ovary account for only 0.2% of malignant ovarian tumours. Two-thirds of all patients become apparent due to the tumour's hormone production.
Methods: A 41-year-old patient (gravida 4, para 4) presented with dyspnoea, enlarged abdominal girth and melaena. Diagnostic imaging was suspicious for an ovarian cancer. The standard tumour marker for ovarian cancer (CA 125) was elevated to 984 U/mL.
Results: Surgical exploration of the abdomen revealed a mouldering tumour of both adnexes extending to the level of the navel. Frozen sections showed an undifferentiated carcinoma of unknown origin. Radical surgery was performed. The final histological report described a malignant sex-cord stroma tumour, a Sertoli-Leydig cell tumour, emanating from both ovaries. Analysis of preoperative blood serum showed elevated levels of CYFRA 21-1 (10.4 ng/mL), neuron-specific enolase (36.2 ng/mL), oestradiol (485 pg/mL) and CA-125 (984 U/mL). Adjuvant chemotherapy and regional hyperthermia were performed due to the malignant potential and incomplete resection of the tumour.
Conclusions: Undifferentiated Sertoli-Leydig cell tumours show a poor clinical course. As only two-thirds of patients with this rare disease present with elevated hormone levels, new markers deserve further investigation to offer more specific, individualised tumour monitoring.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/CCLM.2007.120 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A molecular and immunohistochemical study of 37 cases of ovarian Sertoli-Leydig cell tumor.
Virchows Arch
November 2024
Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Article Synopsis
- This study analyzes 37 ovarian Sertoli-Leydig cell tumors (SLCT) with a focus on their morphology, immunohistochemistry, and molecular features, categorizing them into well, moderately, and poorly differentiated tumors.
- High levels of sex cord markers were found, along with variable expression of other markers, and notable mutations like DICER1 (54.5%) and FOXL2 (6%) were identified, suggesting important diagnostic and predictive implications.
- Differences in mRNA expression profiles between DICER1 and non-DICER1 tumors highlight the distinct molecular characteristics of SLCTs, indicating that well-differentiated tumors could represent a unique subtype apart from the others.
Sex cord ovarian tumours over 10 years: a retrospective analysis of clinicopathological profile and outcome.
Ecancermedicalscience
September 2024
Department of Gynaecologic Oncology, Christian Medical College, Vellore 632004, India.
Objectives: To retrospectively describe the clinicopathological profile and treatment outcome of sex cord ovarian tumours (SCOTs), from a single institution.
Methods: Patients who operated for SCOT between January 2011 and December 2020 were identified from the institution's discharge summaries. Treatment details and oncologic outcomes were analyzed using descriptive statistics, SPSS statistics version 21.
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
Clin Cancer Res
December 2024
Medical College of Wisconsin, Milwaukee, Wisconsin.
Article Synopsis
- The study assesses the effectiveness of a dual checkpoint inhibition therapy (ipilimumab and nivolumab) on advanced non-epithelial ovarian cancers (NEOCs) in patients who have no other effective treatments available.
- In a clinical trial involving 17 patients, the therapy showed a 25% overall response rate in those with granulosa cell tumors, with some patients experiencing significant progression-free survival and overall survival benefits.
- However, the therapy had serious side effects, leading to treatment discontinuation in 18% of participants and no positive responses noted in carcinosarcoma cases.
DICER1-Related Tumor Predisposition: Identification of At-risk Individuals and Recommended Surveillance Strategies.
Clin Cancer Res
December 2024
International Pleuropulmonary Blastoma/DICER1 Registry, Children's Minnesota, Minneapolis, Minnesota.
Article Synopsis
- DICER1-related tumor predisposition is linked to an increased risk of both benign and malignant tumors, prompting the need for guidelines on testing and imaging for affected individuals.
- A study enrolled participants from various registries and identified 713 individuals with germline DICER1 variants, leading to the diagnosis of multiple cases of pleuropulmonary blastoma (PPB) and ovarian Sertoli-Leydig cell tumors (SLCT).
- The findings suggest that early imaging and surveillance can help detect PPB and may lower the risk of advanced disease, leading to recommendations for earlier ovarian surveillance beginning at the detection of DICER1 variants.
Does surgery to preserve fertility in Sertoli-Leydig cell tumours increase the likelihood of spontaneous conception?
BMJ Case Rep
October 2024
Reproductive Medicine & Surgery, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, Tamil Nadu, India.
Article Synopsis
- A woman in her 30s experienced primary infertility and secondary amenorrhoea, with signs of virilisation and a solid mass found on her right ovary, leading to concerns about an ovarian tumor.
- Tests indicated the likely presence of an androgen-producing tumor called a Sertoli-Leydig cell tumour (SLCT), which was confirmed through histopathology after a fertility-sparing surgery.
- Following the surgery, the patient’s testosterone levels dropped significantly, and her menstrual cycle resumed, highlighting the importance of recognizing SLCTs in similar cases and considering fertility-preserving options in young women with such conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!